Ideal intraarticular application dose of tranexamic acid in primary total knee arthroplasty: a prospective, randomized and controlled study

Jun Wu¹,², Yi-Qin Zhou¹#, Jian-Hua Deng², Ya-Guang Han¹, Yu-Chang Zhu²,³, Qi-Rong Qian¹

¹Department of Joint Surgery and Sports Medicine, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China; ²Department of Orthopaedic Surgery, Nantong Sixth People’s Hospital, Nantong, China; ³Department of Orthopaedic Surgery, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China

Contributions: (I) Conception and design: J Wu, YC Zhu, QR Qian; (II) Administrative support: QR Qian; (III) Provision of study materials or patients: JH Deng, YC Zhu, QR Qian; (IV) Collection and assembly of data: J Wu, YQ Zhou, YG Han; (V) Data analysis and interpretation: J Wu, YQ Zhou; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

#These authors contributed equally to this work.

Background: Combined use of tranexamic acid (TXA) via intravenous (IV) and intraarticular (IA) routes is more effective in reducing blood loss than any single route in primary total knee arthroplasty (TKA), but the optimal dose of topical administration remains controversial. The aim of this study was to evaluate the efficacy and safety of different combined administration strategies and to determine an ideal IA application dose of TXA.

Methods: A total of 180 patients who underwent primary TKA were randomized to four groups (groups A/B/C/D) with the same single IV dose of 1 g TXA preoperatively and four different IA doses after wound closure: group A (0 g), group B (1 g), group C (2 g), and group D (4 g). The primary outcome measures included wound blood drainage, hemoglobin (Hb) concentration, and blood transfusion. The secondary outcome measures included wound complications, deep vein thrombosis (DVT) and symptomatic pulmonary embolism (PE).

Results: A total of 165 patients finished at least 3 months of follow-up visits. The amount of 48-hour blood drainage and calculated total blood loss in four groups decreased with the increased dose of TXA injected via IA route, and no difference was observed between groups C and D (P=0.6237 and P=0.9923, respectively). Hb was significantly higher in groups C and D than in groups A and B at postoperative day 1, 3 and 7, respectively (P<0.0001). Hb in group A was significantly lower than that in groups C and D at 1 month after surgery, whereas no intergroup difference was found in other groups. No intergroup difference was observed regarding DVT, PE or wound complications.

Conclusions: The topical injection of 2 g TXA may have reached the “ceiling effect” of local use. A preoperative IV dose of 1 g TXA combined with an IA dose of 2 g TXA could be an optimal combination regimen.

Keywords: Tranexamic acid (TXA); total knee arthroplasty (TKA); intra-articular injection; topical use

Submitted Apr 01, 2020. Accepted for publication Sep 25, 2020.
doi: 10.21037/atm-20-3064

View this article at: http://dx.doi.org/10.21037/atm-20-3064
Introduction

Total knee arthroplasty (TKA) is a well-accepted surgical treatment with reliable results for knee joint diseases. With increases in life expectancy and improvements in medical care, an increasing number of patients will receive TKA (1). During the past decade, tremendous efforts have been made to achieve quick recovery in functional performance after TKA. Such efforts based on a multimodal “fast track” methodology focus on pain relief, early mobilization, and reduced blood loss, leading to a reduction in the length of hospital stay as well as early recovery of knee function (2). Nonetheless, intraoperative and postoperative bleeding remains an essential issue in TKA, causing swelling, pain, anemia and anxiety, followed by prolonged hospital stays, increased medical costs, and impaired early postoperative recovery. It has been reported that patients can lose as much as 1,450 mL of blood during TKA without intervention, and that approximately 10% of patients require blood transfusions due to symptomatic anemia, which can be fatal to elderly patients with cardiopulmonary insufficiency (3). Therefore, approaches to effectively reduce blood loss during the perioperative period are of continuing interest.

The use of tranexamic acid (TXA) in total knee and hip arthroplasty has been well established in recent years. In TKA, both the intravenous (IV) and intraarticular (IA) (or topical) administration of TXA have been shown to effectively reduce blood loss after surgery. A number of meta-analyses and prospective clinical studies have shown that a combined IV and IA regimen of TXA seems to be one of the most effective methods to reducing postoperative blood loss, without severe thromboembolic complications (4-8), and usually, the IV administration of TXA in clinical practice is set to 10–20 mg/kg according to the instruction manual. Nevertheless, the indications and dose for its local use are not clear. Most of the time, the topical dose is based on clinical experience and recommendations from the so-called “Orthopedic Experts’ Consensus”, and the optimal dose and safety of intra-articular administration remain controversial. In our previous study (9), different combined administration strategies of TXA were investigated, and the preliminary results confirmed that the amount of blood loss decreased with the increase in the dose of TXA administered via IA injection. However, we did not find a meaningful difference in the hemostatic effect between IA injections of 2 and 3 g, which may be due to the “ceiling effect” or the gentle gradient between the experimental groups. Thus, based on the pilot study, this prospective, randomized and controlled study was conducted to further investigate the effect and safety of single IV administration and different combined administration regimens of TXA in primary TKA and to determine the optimal IA dose with relatively good titers. We present the following article in accordance with the CONSORT reporting checklist (available at http://dx.doi.org/10.21037/atm-20-3064).

Methods

Study design

This prospective, randomized, controlled study was registered in the Chinese Clinical Trial Registry (ChiCTR-TRC-1800018751). The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). Approval was obtained from the Ethics Committee of Nantong Sixth People's Hospital (Approval No. 201704), and written informed consent was obtained from all participants.

Inclusion and exclusion criteria

The inclusion criteria were as follows: (I) patients with unilateral degenerative osteoarthritis of the knee according to diagnostic criteria for knee osteoarthritis (ICD-10 M17.901); (II) normal preoperative hemoglobin (Hb) levels (120 g/L ≤ Hb ≤ 160 g/L in males and 110 g/L ≤ Hb ≤ 150 g/L in females), normal coagulation function and renal function; (III) normal deep veins in the legs on color Doppler echography; and (IV) stable concurrent chronic diseases, if any.

The exclusion criteria were as follows: (I) patients with anemia (Hb <120 g/L in males and Hb <110 g/L in females); (II) patients with abnormal coagulation function; (III) patients with liver or kidney dysfunction (patients with any abnormality in major items of liver and renal hematological examinations or abnormal preoperative urinalysis); (IV) patients with a history of bleeding disorders; (V) patients with a history of deep vein thrombosis (DVT); (VI) patients with hypercoagulability or risk factors for thrombosis (e.g., atrial fibrillation, coronary stenting, tumors, or long-term use of hormones); and (VII) patients with a known history of TXA hypersensitivity.

Sample size calculation

A prior calculation was conducted to determine the sample
size with 80% power at a 5% significant level. A blood loss of 400 mL is generally considered clinically significant. In patients with a mean Hb concentration of 130 g/L, 400 mL blood would contain 52 g Hb, equal to the Hb content of one unit of red cell. Total blood loss during TKA was approximately 1,500 mL without intervention, as previously described (3). To obtain statistical power, 31 patients were required in each group and the recruitment goal was determined to be 180 patients as anticipating a drop-out rate of approximately 20%.

Patient and trial intervention

From August 2017 to February 2019, a total of 180 patients who met the inclusion criteria indicated above were enrolled in this study. A total of 109 patients underwent left TKA, and 71 patients underwent right TKA. The enrolled patients were randomly allocated into four groups by Microsoft Excel software, version 2016 (Microsoft Corporation, Redmond, WA, USA): groups A, B, C and D, with 45 patients each. The same single dose of TXA was administered through IV injection 30 minutes before tourniquet inflation, and different doses of TXA were administered through IA injection via the drainage tube after wound closure: group A (1 g IV + saline with no TXA), group B (1 g IV + 1 g IA), group C (1 g IV + 2 g IA), and group D (1 g IV + 4 g IA). (Figure 1).

Sex, age, body mass index (BMI), severity of osteoarthritis (Kellgren-Lawrence Classification of Osteoarthritis), preoperative Hb concentration, platelet (PLT) count, preoperative prothrombin time (PT) and activated partial thromboplastin time (APTT) were recorded.

Surgical procedure and perioperative management

General anesthesia was adopted. Second-generation cephalosporin antibiotics were used for prophylaxis of infection 30 minutes before the start of surgery. The standard medial parapatellar approach and posterior stabilized cemented prosthesis (NexGen® LPS; Zimmer Biomet, Warsaw, IN, USA) without patellar resurfacing was applied for TKA. One gram of TXA was administered intravenously thirty minutes before tourniquet inflation in all four groups. After the surgical incision was closed, 50 mL of TXA-saline solution (TXA: group A: 0 g; group B: 1 g; group C: 2 g; group D: 4 g) was injected into the joint cavity via the drainage tube. The drainage tube was clamped for 1 hour before suction.

Postoperative management was based on the “Experts’ consensus in enhanced recovery after total hip and knee surgery.”

Figure 1 CONSORT flow diagram of patients eligible for this study. CONSORT, Consolidated Standards of Reporting Trials; TXA, tranexamic acid; IV, intravenous; IA, intraarticular.
arthroplasty in China: perioperative management” (10). The drainage tube was removed 48 hours after surgery.

All procedures were performed by the same senior surgeon experienced in TKA. The patients, surgeons, ward nurses, and researchers were blinded to the patient grouping. The nurses who administered TXA during surgery did not participate in postoperative care, follow-up visits or data analysis.

**Prophylaxis of deep vein thromboembolism (DVT)**

A combination of physical and chemical prophylaxis of DVT was administered according to standard practice (11,12). All patients received lower-extremity muscle strength training preoperatively and started passive and active physical therapy after anesthesia resolution. A lower-extremity inflatable venous pump was applied on the first postoperative three days. All patients were encouraged to walk as far as possible in the inpatient ward. Low-molecular-weight heparin (4000 Axa IU, Clexane, sodium injection) was first administered 12 hours after surgery and then every 24-hour until discharge. An additional 10 mg/day of Rivaroxaban was prescribed for 3 weeks after hospital discharge.

**Blood transfusion protocol**

The perioperative blood transfusion protocol was standardized according to the guidelines provided by the National Health Commission of the People’s Republic of China. According to this protocol, a blood transfusion was indicated when the Hb concentration was <70 g/L or when a patient developed any anemia-related organ dysfunction, such as an alteration in mental status or palpitation (regardless of the Hb concentration), especially in elderly patients with poor heart and lung function.

**Outcome measures**

The primary outcome measures were postoperative blood drainage, Hb concentration, and units of blood transfusion. Routine blood tests were performed at 1, 3, 7 and 30 days after surgery. Total blood loss was calculated according to the Good's formula (13):

$$\text{Hb}_{\text{loss}} = \text{BV} \times (\text{Hb}_i - \text{Hb}_e) \times 0.001 + \text{Hb}_t$$  \[1\]

where \(\text{Hb}_{\text{loss}}\) (g) is the amount of Hb lost, \(\text{BV}\) is the blood volume (mL), \(\text{Hb}_i\) (g/L) is the Hb concentration before surgery, \(\text{Hb}_t\) (g/L) is the Hb concentration on the 5th day after surgery and \(\text{Hb}_e\) (g) is the total amount of allogeneic Hb transfused. One unit of banked red blood cell was considered to contain 50 g Hb according to measurement at our hospital blood center. In this study, \(\text{Hb}\) value on the 7th day after surgery was used to replace that on the 5th day in the Good’s formula. The blood loss (ml) was related to the patient’s preoperative Hb value (g/L):

$$\text{Blood loss} = 1000 \times \frac{\text{Hb}_{\text{loss}}}{\text{Hb}_i}$$  \[2\]

\(\text{BV}\) was estimated according to the method of Nadler and colleagues (14), taking body height, weight, and sex into account:

$$\text{BV} = K_1 \times \text{height}^3 + K_2 \times \text{weight} + K_3$$  \[3\]

In males, \(K_1 = 0.3669\), \(K_2 = 0.03219\), \(K_3 = 0.6041\); in females, \(K_1 = 0.3561\), \(K_2 = 0.03308\), \(K_3 = 0.18333\). The secondary outcome measures were the incidence of thromboembolic events, including DVT and pulmonary embolism (PE). Doppler echography was performed to screen for DVT in the lower legs at 1 week, 1 month, and 3 months after surgery, and symptomatic PE was recorded. At each follow-up visit, the KSS scale was used to assess the patients’ knee joints for pain, stability, and function.

**Data analysis**

The statistical analysis was performed using Prism software, version 8.0.2 (GraphPad Software Inc., San Diego, CA, USA). Prior to data analysis, potential confounders (demographic data, preoperative laboratory values and severity of osteoarthritis) among the study groups as well as primary and secondary outcomes were evaluated for distribution with summary statistics, including the mean and standard deviation for normally distributed quantitative data and percentage for qualitative data. Binomial data are presented as the number and percentage. One-way analysis of variance (One-way ANOVA) was used for comparisons of continuous variables between groups. Non-normally distributed quantitative data were compared using rank-sum tests. The chi-square test was applied to compare differences in categorical data between groups. \(P<0.05\) was considered statistically significant.

**Results**

The postoperative follow-up visit was scheduled for the four groups of patients on a regular basis. A total of 40, 42, 41, and 42 patients in groups A, B, C, and D, respectively, received at least 3 months of follow-up. Fifteen patients did not complete the full duration of follow-up because of
migration or nonnative identity.

No significant between-group differences were observed for any demographic, clinical, or outcome variable, and baseline characteristics were comparable among the groups (Table 1). Females accounted for 59.4% of all the study participants. The mean patient age was 70.9±5.8 years (range, 62 to 81 years), and the mean BMI was 24.0±2.8 kg/m². The mean preoperative Hb level was 127.4±6.0 g/L, and the mean surgical time was 89.1±8.8 minutes. There was no difference in the severity of osteoarthritis among the

### Table 1 Comparison of baseline data among 4 groups

<table>
<thead>
<tr>
<th>Baseline data</th>
<th>Group A (IV 1 g + IA 0 g)</th>
<th>Group B (IV 1 g + IA 1 g)</th>
<th>Group C (IV 1 g + IA 2 g)</th>
<th>Group D (IV 1 g + IA 4 g)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (male/female)</td>
<td>17/28</td>
<td>17/28</td>
<td>18/27</td>
<td>21/24</td>
<td>0.8035</td>
</tr>
<tr>
<td>Age (years)</td>
<td>69.4±5.7</td>
<td>71.7±6.2</td>
<td>72.1±5.1</td>
<td>70.8±5.9</td>
<td>0.0683</td>
</tr>
<tr>
<td>Body weight (kg)</td>
<td>66.0±6.7</td>
<td>66.0±6.7</td>
<td>66.5±7.0</td>
<td>66.7±5.8</td>
<td>0.9408</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>24.4±2.9</td>
<td>23.9±2.8</td>
<td>24.1±2.9</td>
<td>23.6±2.5</td>
<td>0.5777</td>
</tr>
<tr>
<td>Kellgren-Lawrence (III/IV)</td>
<td>23/22</td>
<td>21/24</td>
<td>26/19</td>
<td>25/20</td>
<td>0.7255</td>
</tr>
<tr>
<td>PT (s)</td>
<td>11.9±0.5</td>
<td>12.1±0.6</td>
<td>12.0±0.7</td>
<td>11.9±0.6</td>
<td>0.3383</td>
</tr>
<tr>
<td>APTT (s)</td>
<td>29.9±4.0</td>
<td>30.7±3.1</td>
<td>30.7±3.0</td>
<td>31.0±3.0</td>
<td>0.4332</td>
</tr>
<tr>
<td>PLT (×10⁹/L)</td>
<td>220±23</td>
<td>216±63</td>
<td>233±64</td>
<td>218±60</td>
<td>0.4580</td>
</tr>
<tr>
<td>ASA (I/II/III)</td>
<td>21/19/5</td>
<td>26/17/2</td>
<td>29/15/1</td>
<td>27/15/3</td>
<td>0.5187</td>
</tr>
<tr>
<td>Pre-o. Hb (g/L)</td>
<td>127.1±4.9</td>
<td>127.8±6.7</td>
<td>128.3±6.0</td>
<td>126.5±6.2</td>
<td>0.5056</td>
</tr>
</tbody>
</table>

BMI, body mass index; ASA, American Society of Anesthesiology; Hb, hemoglobin; Pre-o., preoperative; BMI, body mass index; Kellgren-Lawrence, The Kellgren-Lawrence Classification grading system of osteoarthritis; PT, prothrombin time; APTT, activated partial thromboplastin time; PLT, platelets count; ASA, American Society of Anesthesiology; Pre-o., preoperative; Hb, hemoglobin.

<table>
<thead>
<tr>
<th>Postoperative outcome</th>
<th>Group A (IV 1 g + IA 0 g)</th>
<th>Group B (IV 1 g + IA 1 g)</th>
<th>Group C (IV 1 g + IA 2 g)</th>
<th>Group D (IV 1 g + IA 4 g)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgical time (minutes)</td>
<td>89.8±5.7</td>
<td>88.7±9.5</td>
<td>87.9±9.4</td>
<td>90.0±9.6</td>
<td>0.6043</td>
</tr>
<tr>
<td>P.O. 1st day, Hb (g/L)</td>
<td>93.8±4.6*</td>
<td>101.5±4.4*</td>
<td>108.4±5.1*</td>
<td>113.3±4.9*</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>P.O. 3rd day, Hb (g/L)</td>
<td>75.9±3.9ab</td>
<td>81.7±3.7ab</td>
<td>93.6±5.0a</td>
<td>94.7±3.6b</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>P.O. 7th day, Hb (g/L)</td>
<td>88.4±2.5cd</td>
<td>91.3±5.3cd</td>
<td>103.1±4.5c</td>
<td>103.7±4.8d</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>P.O. 30th day, Hb (g/L)</td>
<td>123.6±4.3ef</td>
<td>125.2±3.8</td>
<td>127.2±4.5e</td>
<td>126.5±4.9f</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>48-h drainage (mL)</td>
<td>529.0±71.2gh</td>
<td>478.5±76.2gh</td>
<td>338.4±47.7h</td>
<td>341.2±68.1h</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Patients transfused</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>–</td>
</tr>
<tr>
<td>Transfusion units (U)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>–</td>
</tr>
<tr>
<td>DVT/PE</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>–</td>
</tr>
<tr>
<td>Wound complication (infection/fat liquefaction/skin necrosis)</td>
<td>0/0/0</td>
<td>0/0/0</td>
<td>0/0/1</td>
<td>0/1/0</td>
<td>–</td>
</tr>
</tbody>
</table>

In the table, matched letters superscript indicated significant differences between matched groups (P<0.05). If the superscripts above any two value are the same or containing one same letter, it means that there is statistical difference between these two groups. If the superscripts on any two value have no matched letter, which means there is no statistical difference for comparison between these two groups. * means significant differences among four groups; ‡, comparison of 48-hour drainage between 2 of 4 groups was shown in Table 3. Hb, hemoglobin; P.O., postoperative; DVT, deep vein thrombosis; PE, pulmonary embolism.
As summarized in Table 2, the mean postoperative 48-hour blood drainage volume was 529.0±71.2, 478.5±76.2, 338.4±47.7 and 341.2±68.1 mL for groups A, B, C, and D, respectively. Without considering hidden blood loss, groups C and D had lower outer wound drainage than groups A and B. Compared with group A, groups C and D had lower mean drainage volumes of 190.6 mL (95% CI, 152.1 to 229.1 mL, P<0.0001) and 187.8 mL (95% CI, 149.5 to 226.1 mL, P<0.0001), respectively; compared with group B, groups C and D had lower mean drainage volume of 140.1 mL (95% CI, 102.1 to 178.1 mL, P<0.0001) and 137.3 mL (95% CI, 99.50 to 175.1 mL, P<0.0001), respectively. Moreover, a significantly lower drainage volume was observed in group B than in group A (50.5 mL, 95% CI, 12.23 to 88.77 mL, P=0.0043). For groups C and D, no difference was observed (P=0.9975) (Table 3, Figure 2). The Hb levels in groups C and D were statistically significant only on day 1 after surgery (P<0.0001). The Hb levels in group A were significantly lower than those in groups C and D at 1 month after surgery (P=0.0047 and P=0.0343, respectively), while only minor intergroup differences were recorded among the other groups (Table 2, Figure 3).

The calculated total blood loss was 1249.72±266.38, 1047.36±281.74, 839.17±272.08, and 822.74±247.55 mL in groups A, B, C, and D, respectively. With the increase of IA dose, total blood loss showed a decreasing trend. There were significant differences between groups except for group C and D, which were highly consistent with those on 48-hour drainage (Table 4). No patient in any group received an allogeneic blood transfusion postoperatively. One patient in group C had skin margin necrosis, and one patient in group D developed incision fat tissue liquefaction, which manifested as delayed wound healing, with continuous yellow exudation containing small lipid droplets and no bacterial or fungal growth in the microbial culture. Secondary debridement and re-suturing were performed on
days 10 and 15 after surgery, respectively. The remaining patients were discharged from the hospital within 1 week after surgery.

At the follow-up 3 months after surgery, the KS-C scores were 90.0±6.6, 89.1±3.9, 90.9±5.6, and 88.9±7.9 in groups A, B, C, and D, respectively. The KS-F scores was 86.4±3.6, 85.6±8.1, 87.1±7.3 and 86.8±6.0 in group A, B, C, and D, respectively. There was no statistically significant difference among the four groups, regarding KS-C (P=0.4351) or KS-F (P=0.7412). No episodes of DVT occurred in any patient, and no symptomatic PE was reported in any of the four groups.

**Discussion**

The current well-accepted theory states that hyperfibrinolysis after TKA is an important factor causing massive blood loss. Based on this theory, the use of the antifibrinolytic agent TXA during the perioperative period of TKA can theoretically reduce postoperative blood loss and the need for blood transfusions (15). TXA, a synthetic derivative of lysine, can competitively inhibit plasminogen activation and the combination of fibrin and plasmin and stabilize blood clots and decrease the fibrinolytic process, playing a key role in reducing bleeding (16,17).

To date, most studies have focused on different ways and frequencies of drug administration. However, no consensus on the ideal dose of combination administration has been reached, especially for IA injection.

In our previous study (9), we directly compared three
Vaughan, et al. (26) noted that prolonged anticoagulant therapy and related hypercoagulation for a considerable period after surgery results in patients being in a state of hypercoagulation. However, we must still emphasize that patients will be in a state of hypercoagulation for a considerable period of time after surgery (26) and that prolonged anticoagulant therapy and domestic rehabilitation are strongly recommended.

For one patient with skin margin necrosis in group C and one patient with fat tissue liquefaction in group D, no severe incisional complications were recorded. These two patients achieved secondary healing after debridement and re-suturing. To the best of our knowledge, there is no firm evidence to indicate that skin incision necrosis or fat tissue liquefaction is related to TXA. Yuan et al. (27) noted that a high concentration of TXA injected into the joint cavity may over-activate anti-fibrinolysis and that excessive blood clot formation may block the drainage tube, resulting in local hematoma, joint swelling, and wound dehiscence. Although few side effects or complications related to topical use have been reported, poor healing of the incision will lead to prolonged hospital stays, which will inevitably increase medical costs and the risk of nosocomial joint infection, which is disastrous for joint replacement. We believe that it is necessary for clinicians to pay attention to this potential risk, especially in China, which has an extremely discordant doctor-patient relationship (28).

As such, poor results might further aggravate this tense relationship.

In brief, from the perspective of pharmacokinetics, combined with the same single-dose of IV injection, the hemostatic effect of the topical injection of 2 g TXA was better than that of 1 g TXA or placebo and comparable to that of 4 g TXA. Regarding to the relationship between coagulation and anticoagulation in most orthopedic surgeries, TXA itself is a double-edged sword. Theoretically, the lower the topical concentration of TXA is, the lower the risk of thromboembolic side-effects. Regardless of whether TXA is used systemically or topically, it is worthwhile to be vigilant that a low-dose regimen is always preferable in cases in which the effect of TXA is the same.

Several limitations of this study should be mentioned. (I) We mainly collected and analyzed postoperative blood loss through the drainage tube and just calculated total blood loss based on formula. Thus, the actual total blood loss was imprecise and may be underestimated. (II) The dose and frequency of the IV administration of TXA are still controversial. In this study, we administered only a single IV
dose of TXA before surgery based on previously reported RCTs. Further studies should be carried out to verify whether this is the best regimen and the frequencies of IV injection. (III) The clamping time of the drainage tube after surgery is rarely reported in the existing literature, and it was set at 1 hour based on a few clinical studies. Whether 1 hour is an optimal time needs further study. (IV) Doppler ultrasonography instead of venography was used to rule out DVT. PE was excluded through clinical observation rather than CTA. Therefore, diagnoses may have been missed in some patients with mild signs. (V) Because of the number of patients, this study was underpowered to draw any meaningful conclusion with regard to safety. Multicenter prospective studies with a larger number of patients can help address these issues and verify the conclusion of the present study.

Conclusions

In conclusion, the combined use strategy of TXA in TKA can more effectively reduce blood loss after surgery than a single IV injection of TXA and may not increase the risk of thromboembolic disease. The topical injection of 2 g TXA may have reached the “ceiling effect” of local use. The preoperative IV injection of 1 g TXA combined with the IA topical injection of 2 g TXA after wound closure can effectively reduce postoperative blood loss, making it an optimal combination drug regimen.

Acknowledgments

Funding: None.

Footnote

Reporting Checklist: The authors have completed the CONSORT reporting checklist. Available at http://dx.doi.org/10.21037/atm-20-3064

Data Sharing Statement: Available at http://dx.doi.org/10.21037/atm-20-3064

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-20-3064). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). Ethics approval was obtained from the Ethics Committee of Nantong Sixth People’s Hospital (Approval No. 201704), and written informed consent was obtained from all participants.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References


